News

The National Institute for Health and Care Excellence6h
New cystic fibrosis drug fast-tracked for NHS use
Alyftrek (vanzacaftor–tezacaftor–deutivacaftor), made by Vertex, represents the latest advance in CFTR modulator treatments that are transforming cystic fibrosis care by targeting the underlying cause ...
The National Institute for Health and Care Excellence9d
10 Year Health Plan empowers NICE to get patients better care, faster
The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At ...
The National Institute for Health and Care Excellence13d
NICE welcomes the inclusion of measures for equal treatment of medicines and health technologies
The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...
National Institute for Health and Care Excellence5d
Published guidance, NICE advice and quality standards
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
National Institute for Health and Care Excellence15y
Unstable angina and NSTEMI: early management - NICE
Unstable angina and NSTEMI: early management Clinical guideline CG94 Published: 24 March 2010 Last updated: 01 November 2013 ...
National Institute for Health and Care Excellence13d
NICE newsletters and alerts
Subscribe to our newsletters, alerts and awareness service. Keep up to date with the latest evidence based information across health and social care.
National Institute for Health and Care Excellence10y
Obesity: identification, assessment and management
This guideline has been updated and replaced by the NICE guideline on overweight and obesity management (NG246) ...
National Institute for Health and Care Excellence6y
Durvalumab for treating locally advanced unresectable non-small-cell ...
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation Technology appraisal guidance TA578 Published: 01 May 2019 ...
National Institute for Health and Care Excellence5y
Overview | Cellulitis and erysipelas: antimicrobial prescribing ...
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use ...
National Institute for Health and Care Excellence4y
Overview | Trastuzumab deruxtecan for treating HER2-positive ...
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults after 2 or more anti-HER2 therapies. Last reviewed: 26 ...
National Institute for Health and Care Excellence5y
Olaparib for maintenance treatment of BRCA mutation-positive advanced ...
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal ...
National Institute for Health and Care Excellence3y
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small ...
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Technology appraisal guidance TA761 Published: 19 January 2022 ...